Epizyme General and Administrative Expenses | EPZM

General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.

What these expenses include

Salaries of administrative staff (executives, HR, accountants, legal personnel)
Office rent and utilities
Office equipment and IT infrastructure
Professional services (auditors, lawyers, consultants)
Insurance
General administrative travel and representation expenses

What the metric indicates

Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure
Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit
Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry
Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines

Annual General and Administrative Expenses Epizyme

2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010
134 M	125 M	23.5 M	12.2 M	37.2 M	28.4 M	23.9 M	20.9 M	14 M	7.51 M	5 M	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
134 M	5 M	39.2 M

Quarterly General and Administrative Expenses Epizyme

2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	24.1 M	27.2 M	-	32.8 M	33.9 M	36.4 M	35 M	30.6 M	32.7 M	26.9 M	23.5 M	17.1 M	15.7 M	12 M	12.2 M	11.5 M	10.9 M	9.36 M	8.43 M	9.31 M	11.2 M	8.27 M	7.58 M	7.52 M	7.42 M	5.85 M	6.02 M	6.68 M	5.97 M	5.24 M	4.94 M	5.67 M	5.31 M	4.96 M	4.38 M	3.59 M	3.08 M	3 M	2.33 M	1.63 M	1.64 M	1.91 M	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
36.4 M	1.63 M	12.8 M

General and Administrative Expenses of other stocks in the Biotechnology industry

Issuer	General and Administrative Expenses	Price	% 24h	Market Cap	Country
ContraFect Corporation CFRX	12.2 M	-	-5.16 %	$ 5.39 M	USA
Turning Point Therapeutics TPTX	75.8 M	-	-0.13 %	$ 3.73 B	USA
Forward Pharma A/S FWP	3.65 M	-	-0.75 %	$ 18.7 M	Danmark
Gamida Cell Ltd. GMDA	19.8 M	-	-18.25 %	$ 5.04 M	Israel
Regulus Therapeutics RGLS	14.7 M	-	-	$ 155 M	USA
Marinus Pharmaceuticals MRNS	61.2 M	-	-	$ 29.6 M	USA
NeuBase Therapeutics NBSE	2.6 M	-	-1.56 %	$ 12.3 M	USA
Arena Pharmaceuticals ARNA	126 M	-	-6.81 %	$ 3.04 B	USA
Scopus BioPharma SCPS	9.03 M	-	-48.37 %	$ 3.71 M	USA
scPharmaceuticals SCPH	77.6 M	-	-	$ 218 M	USA
Athersys ATHX	15.9 M	-	3.77 %	$ 22.4 M	USA
Seagen SGEN	821 M	-	-	$ 42.2 B	USA
Sigilon Therapeutics SGTX	19 M	-	-	$ 728 M	USA
Rubius Therapeutics RUBY	30.8 M	-	-33.55 %	$ 7.81 M	USA
TRACON Pharmaceuticals TCON	6.67 M	-	-1.38 %	$ 46.8 M	USA
Revance Therapeutics RVNC	298 M	-	-	$ 309 M	USA
Sierra Oncology SRRA	27.4 M	-	-0.05 %	$ 1.34 B	Canada
Vaccinex VCNX	6.79 M	-	-61.37 %	$ 654 K	USA
Forma Therapeutics Holdings FMTX	48.3 M	-	-	$ 958 M	USA
Bellicum Pharmaceuticals BLCM	5.72 M	-	-9.72 %	$ 5.89 M	USA
Blueprint Medicines Corporation BPMC	359 M	-	-	$ 8.14 B	USA
Paratek Pharmaceuticals PRTK	146 M	-	-	$ 121 M	USA
ASLAN Pharmaceuticals Limited ASLN	13.2 M	-	-14.27 %	$ 1.7 M	Singapore
Acorda Therapeutics ACOR	89.7 M	-	-24.86 %	$ 820 K	USA
Ampio Pharmaceuticals AMPE	7.08 M	-	-11.43 %	$ 502 K	USA
Nabriva Therapeutics plc NBRV	45.3 M	-	-	$ 4.55 M	Irlanda
NGM Biopharmaceuticals NGM	37.8 M	-	-	$ 127 M	USA
Unity Biotechnology UBX	15.5 M	-	-33.41 %	$ 3.37 M	USA
Aravive ARAV	13 M	-	-13.39 %	$ 1.45 M	USA
Titan Pharmaceuticals TTNP	4.56 M	-	-3.76 %	$ 3.47 M	USA
iTeos Therapeutics ITOS	49.1 M	-	-	$ 411 M	USA
Allena Pharmaceuticals ALNA	12.7 M	-	3.16 %	$ 1.9 M	USA
Alpine Immune Sciences ALPN	22.2 M	-	-	$ 2.17 B	USA
TCR2 Therapeutics TCRR	24.4 M	-	-	$ 58.1 M	USA
CymaBay Therapeutics CBAY	52 M	-	-	$ 3.45 B	USA
Aridis Pharmaceuticals ARDS	7.16 M	-	17.91 %	$ 11.1 M	USA
TFF Pharmaceuticals TFFP	10.6 M	-	-60.05 %	$ 125 K	USA
Theratechnologies THTX	14.6 M	-	-	$ 83.9 M	Canada
Timber Pharmaceuticals TMBR	6.02 M	-	-	$ 717 K	USA
Adaptimmune Therapeutics plc ADAP	87.3 M	-	-15.15 %	$ 60.3 M	Britain
Advaxis ADXS	12.2 M	-	-9.65 %	$ 45.9 M	USA
Axcella Health AXLA	15.8 M	-	-16.42 %	$ 249 M	USA
Tyme Technologies TYME	9.63 M	-	8.07 %	$ 54 M	USA
Vascular Biogenics Ltd. VBLT	10.1 M	-	-8.77 %	$ 12.4 M	Israel
Berkeley Lights BLI	95.1 M	-	-7.31 %	$ 87 M	USA
Codiak BioSciences CDAK	27.6 M	-	-55.98 %	$ 2.15 M	USA
Cerevel Therapeutics Holdings CERE	113 M	-	-	$ 7.29 B	USA
Checkpoint Therapeutics CKPT	20.1 M	-	-	$ 169 M	USA
Sage Therapeutics SAGE	216 M	-	-	$ 527 M	USA